Amanda Cano1,2,3, Miren Ettcheto3,4,5, Marta Espina1,2, Carmen Auladell6, Jaume Folch3,5, Britta A Kühne4, Marta Barenys4, Elena Sánchez-López1,2,3, Eliana B Souto7,8, Maria Luisa García1,2, Patric Turowski9, Antonio Camins3,4. 1. Department of Pharmacy, Pharmaceutical Technology & Physical Chemistry, Faculty of Pharmacy & Food Sciences, University of Barcelona, Barcelona, Spain. 2. Institute of Nanoscience & Nanotechnology (IN2UB), Barcelona, Spain. 3. Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain. 4. Department of Pharmacology, Toxicology & Therapeutic Chemistry, Faculty of Pharmacy & Food Sciences, University of Barcelona, Spain. 5. Unit of Biochemistry & Pharmacology, Faculty of Medicine & Health Sciences, University of Rovira i Virgili, Reus (Tarragona), Spain. 6. Department of Cellular Biology, Physiology & Immunology, Faculty of Biology, University of Barcelona, Spain. 7. Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal. 8. CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar 4710-057 Braga, Portugal. 9. UCL Institute of Ophthalmology, University College of London, London, UK.
Abstract
Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntington's disease (HD)-like symptoms in mice. Materials & methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.
Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntington's disease (HD)-like symptoms in mice. Materials & methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.
Authors: Abdul Waris; Asmat Ali; Atta Ullah Khan; Muhammad Asim; Doaa Zamel; Kinza Fatima; Abdur Raziq; Muhammad Ajmal Khan; Nazia Akbar; Abdul Baset; Mohammed A S Abourehab Journal: Nanomaterials (Basel) Date: 2022-06-22 Impact factor: 5.719
Authors: Xavier Roig-Soriano; Eliana B Souto; Firas Elmsmari; Maria Luisa Garcia; Marta Espina; Fernando Duran-Sindreu; Elena Sánchez-López; Jose Antonio González Sánchez Journal: Pharmaceutics Date: 2022-07-21 Impact factor: 6.525